HZNP:NGS-Horizon Pharma plc

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing Price

USD 13.71

Change

0.00 (0.00)%

Market Cap

USD 2.26B

Volume

1.49M

Yahoo Analyst Target

USD 19.58 (42.82%)

STA Analyst Target

USD 18.55 (35.27%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Horizon Pharma PLC is a specialty pharmaceutical company. The Company's product portfolio consists of ACTIMMUNE, DUEXIS, PENNSAID 2% and RAYOS/LODOTRA, which addresses the unmet therapeutic needs in arthritis, pain, inflammatory and/or orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-04-21 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
MYL Mylan N.V.

N/A

USD 20.96B
HCM Hutchison China MediTech Limit..

N/A

USD 4.38B
GWPH GW Pharmaceuticals Plc

N/A

USD 3.74B
IRWD Ironwood Pharmaceuticals Inc.

N/A

USD 2.61B
SUPN Supernus Pharmaceuticals Inc.

N/A

USD 2.50B
AKRX Akorn Inc.

N/A

USD 2.47B
HRTX Heron Therapeutics Inc.

N/A

USD 2.20B
MDCO The Medicines Company

N/A

USD 2.16B
AERI Aerie Pharmaceuticals Inc.

N/A

USD 2.12B
PAHC Phibro Animal Health Corporati..

N/A

USD 1.77B

ETFs Containing HZNP

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.10% 38% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.10% 38% F 30% F
Trailing 12 Months  
Capital Gain -8.54% 49% F 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.54% 49% F 27% F
Trailing 5 Years  
Capital Gain 461.89% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 461.89% 94% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 74.13% 95% A 97% A+
Dividend Return 74.13% 95% A 97% A+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 150.19% 6% F 3% F
Risk Adjusted Return 49.36% 90% A- 55% F
Market Capitalization 3.42B 91% A- 82% B-

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -5.44 59% F 75% C
Price/Book Ratio 2.25 57% F 47% F
Price / Cash Flow Ratio 1.75 24% F 54% F
Price/Free Cash Flow Ratio 8.11 17% F 47% F
Management Effectiveness  
Return on Equity -38.86% 57% F 23% F
Return on Invested Capital -13.33% 69% D+ 29% F
Return on Assets -9.73% 70% C- 30% F
Debt to Equity Ratio 180.75% 22% F 12% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

HZNP:NGS-Horizon Pharma plc

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing Price

USD 13.71

Change

0.00 (0.00)%

Market Cap

USD 2.26B

Volume

1.49M

Yahoo Analyst Target

USD 19.58 (42.82%)

STA Analyst Target

USD 18.55 (35.27%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-04-21